-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $38 Price Target

Benzinga·05/19/2026 10:41:40
Listen to the news
BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $38 price target.